# US 2025/0144102 A1 · 1 h-pyrazolo[4,3-d]pyrimidine derivatives as staphylococcus aureus inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144102 A1
- Document ID: US20250144102A1
- Status: Published application
- Kind: A1
- Application number: 18/834,944
- Filed: 2023-02-01
- Published: 2025-05-08
- Earliest claimed: 2022-02-01
- Assignees: Dr. Reddy's Institute of Life Sciences
- Applicants: Dr Reddy's Institute of Life Sciences
- Inventors: Srinivas ORUGANTI; Parimal MISRA; Nasreen Zafar EHTESHAM; Seyed Ehtesham HASNAIN; Manojit PAL
- Web page: https://patentgrep.com/patent/US20250144102A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- C07D 487/04: Ortho-condensed systems
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a compound of Formula (I): [Formula should be inserted here] or a pharmaceutically acceptable salt, a pharmaceutically acceptable stereoisomer, a pharmaceutically acceptable hydrate, a pharmaceutically acceptable solvate, a prodrug, a polymorph, an N-oxide or a bioisostere thereof; wherein “R”, “Ar”, and “Het” are as defined in the specification, which can be used as a medicament or therapeutic agent in the prevention or treatment of a condition or a disease or a disorder where there is an advantage in inhibiting S. aureus or other Gram-positive bacteria.

## Claims

### Claim 1

A method of preventing or treating a condition or a disease or a disorder caused by Staphylococcus aureus (S. aureus) in a subject, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I):
or a pharmaceutically acceptable salt, a pharmaceutically acceptable stereoisomer, a pharmaceutically acceptable hydrate, a pharmaceutically acceptable solvate, a prodrug, a polymorph, an N-oxide or a bioisostere thereof, wherein:
each R is independently selected from hydrogen, halogen, hydroxyl, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heteroaryl;
Ar is an aryl or heteroaryl; and
Het represents an optionally substituted heterocyclyl or heteroaryl connected through a C—C bond.

### Claim 2 (depends on 1)

The method as claimed in claim 1, wherein R is an optionally substituted alkyl.

### Claim 3 (depends on 1)

The method as claimed in claim 1, wherein Ar is aryl.

### Claim 4 (depends on 3)

The method as claimed in claim 3, wherein Ar is phenyl optionally substituted with one or more halo.

### Claim 5 (depends on 1)

The method as claimed in claim 1, wherein Het is an optionally substituted heteroaryl.

### Claim 6 (depends on 5)

The method as claimed in claim 5, wherein Het is selected from the following:
wherein,
R is independently selected from hydrogen, halogen, hydroxyl, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl and optionally substituted heteroaryl;
X is hydrogen or halo; and
Y is hydrogen or halo.

### Claim 7 (depends on 1)

The method as claimed in claim 1, wherein the compound is selected from:
5-(4-chlorophenyl)-7-(1H-indol-3-yl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine;
5-(4-chlorophenyl)-1-methyl-7-(1-methyl-1H-indol-3-yl)-3-propyl-1H-pyrazolo[4,3-d]pyrimidine;
5-(4-chlorophenyl)-7-(1-ethyl-1H-indol-3-yl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine;
7-(5-bromo-1H-indol-3-yl)-5-(4-chlorophenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine;
7-(5-bromo-1-methyl-1H-indol-3-yl)-5-(4-chlorophenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine;
7-(5-bromo-1-ethyl-1H-indol-3-yl)-5-(4-chlorophenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine;
7-(5-chloro-1H-indol-3-yl)-5-(4-chlorophenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine;
7-(5-chloro-6-fluoro-1H-indol-3-yl)-5-(4-chlorophenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine;
5-(4-chlorophenyl)-7-(5,6-difluoro-1H-indol-3-yl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine;
5-(4-chlorophenyl)-7-(5-methoxy-1H-indol-3-yl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine;
4-chlorophenyl)-7-(5-methoxy-1-methyl-1H-indol-3-yl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine;
5-(4-chlorophenyl)-7-(1-ethyl-5-methoxy-1H-indol-3-yl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine; and
7-(1-allyl-1H-indol-3-yl)-5-(4-chlorophenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine;
or a pharmaceutically acceptable salt, a pharmaceutically acceptable stereoisomer, a pharmaceutically acceptable hydrate, a pharmaceutically acceptable solvate, a prodrug, a polymorph, an N-oxide or a bioisostere thereof.

### Claim 8 (depends on 1)

The method as claimed in claim 1, wherein S. aureus is multidrug-resistant Staphylococcus aureus.

### Claim 9

A method of inhibiting S. aureus comprising administering to a subject in a need thereof a therapeutically effective amount of a compound of Formula (I):
or a pharmaceutically acceptable salt, a pharmaceutically acceptable stereoisomer, a pharmaceutically acceptable hydrate, a pharmaceutically acceptable solvate, a prodrug, a polymorph, an N-oxide or a bioisostere thereof, wherein:
each R is independently selected from hydrogen, halogen, hydroxyl, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heteroaryl;
Ar is an aryl or heteroaryl; and
Het represents an optionally substituted heterocyclyl or heteroaryl connected through a C—C bond.

### Claim 10 (depends on 9)

The method as claimed in claim 9, wherein S. aureus is multidrug-resistant Staphylococcus aureus.

### Claim 11

(canceled)

### Claim 12 (depends on 9)

The method as claimed in claim 9, wherein R is an optionally substituted alkyl.

### Claim 13 (depends on 9)

The method as claimed in claim 9, wherein Ar is aryl.

### Claim 14 (depends on 12)

The method as claimed in claim 12 wherein Ar is phenyl optionally substituted with one or more halo.

### Claim 15 (depends on 9)

The method as claimed in claim 9, wherein Het is an optionally substituted heteroaryl.

### Claim 16 (depends on 14)

The method as claimed in claim 14, wherein Het is selected from the following:
wherein,
R is independently selected from hydrogen, halogen, hydroxyl, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocyclyl and optionally substituted heteroaryl;
X is hydrogen or halo; and
Y is hydrogen or halo.

### Claim 17 (depends on 9)

The method as claimed in claim 9, wherein the compound is selected from:
5-(4-chlorophenyl)-7-(1H-indol-3-yl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine;
5-(4-chlorophenyl)-1-methyl-7-(1-methyl-1H-indol-3-yl)-3-propyl-1H-pyrazolo[4,3-d]pyrimidine;
5-(4-chlorophenyl)-7-(1-ethyl-1H-indol-3-yl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine;
7-(5-bromo-1H-indol-3-yl)-5-(4-chlorophenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine;
7-(5-bromo-1-methyl-1H-indol-3-yl)-5-(4-chlorophenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine;
7-(5-bromo-1-ethyl-1H-indol-3-yl)-5-(4-chlorophenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine;
7-(5-chloro-1H-indol-3-yl)-5-(4-chlorophenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine;
7-(5-chloro-6-fluoro-1H-indol-3-yl)-5-(4-chlorophenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine;
5-(4-chlorophenyl)-7-(5,6-difluoro-1H-indol-3-yl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine;
5-(4-chlorophenyl)-7-(5-methoxy-1H-indol-3-yl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine;
4-chlorophenyl)-7-(5-methoxy-1-methyl-1H-indol-3-yl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine;
5-(4-chlorophenyl)-7-(1-ethyl-5-methoxy-1H-indol-3-yl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine; and
7-(1-allyl-1H-indol-3-yl)-5-(4-chlorophenyl)-1-methyl-3-propyl-1H-pyrazolo[4,3-d]pyrimidine;
or a pharmaceutically acceptable salt, a pharmaceutically acceptable stereoisomer, a pharmaceutically acceptable hydrate, a pharmaceutically acceptable solvate, a prodrug, a polymorph, an N-oxide or a bioisostere thereof.

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21 (depends on 8)

The method as claimed in claim 8, wherein multidrug-resistant Staphylococcus aureus is methicillin-resistant Staphylococcus aureus (MRSA), oxacillin-resistant Staphylococcus aureus (ORSA), gentamicin-resistant Staphylococcus aureus (GRSA), or azithromycin-resistant Staphylococcus aureus (ARSA).

### Claim 22 (depends on 17)

The method as claimed in claim 17, wherein multidrug-resistant Staphylococcus aureus is gentamicin-resistant Staphylococcus aureus (GRSA).

### Claim 23 (depends on 10)

The method as claimed in claim 10, wherein multidrug-resistant Staphylococcus aureus is methicillin-resistant Staphylococcus aureus, oxacillin-resistant Staphylococcus aureus (ORSA), gentamicin-resistant Staphylococcus aureus (GRSA), or azithromycin-resistant Staphylococcus aureus (ARSA).

### Claim 24 (depends on 19)

The method as claimed in claim 19, wherein multidrug-resistant Staphylococcus aureus is gentamicin-resistant Staphylococcus aureus (GRSA).
